R. Tommasi

发表

Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors.

P. Atadja, W. Shao, Margaret R Pancost, 2011, Bioorganic & medicinal chemistry.

Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.

B C Finzel, K D Watenpaugh, W. Howe, 1996, Journal of medicinal chemistry.

Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases

S. McLeod, R. Tommasi, M. Sacco, 2020, Journal of medicinal chemistry.

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

D. Ehmann, S. McLeod, Camilo Velez-Vega, 2017, Nature Microbiology.

Whole-Cell-Based Assay To Evaluate Structure Permeation Relationships for Carbapenem Passage through the Pseudomonas aeruginosa Porin OprD.

Camilo Velez-Vega, R. Tommasi, Alita A. Miller, 2017, ACS infectious diseases.

Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics.

R. Tommasi, M. Perros, John P. Mueller, 2021, Drug discovery today.

Novel method for the loading of nucleophiles on multipin crowns

P. Nantermet, R. Tommasi, W. Brill, 1998 .

Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design.

R. Bohacek, H. Zhou, K. Clark, 2001, Journal of medicinal chemistry.

Toward the rational design of carbapenem uptake in Pseudomonas aeruginosa.

R. Tommasi, J. Manchester, Arthur J. Campbell, 2015, Chemistry & biology.

Biophysical Investigation of the Mode of Inhibition of Tetramic Acids, the Allosteric Inhibitors of Undecaprenyl Pyrophosphate Synthase

S. Peukert, Lac V. Lee, R. Tommasi, 2010, Biochemistry.

N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.

R. Tommasi, M. Sacco, April Chen, 2020, Bioorganic & medicinal chemistry.

Optimization of halopemide for phospholipase D2 inhibition.

W. Boyar, R. Tommasi, P. Steed, 2007, Bioorganic & medicinal chemistry letters.

Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.

M. Shultz, Jonathan E. Grob, R. Tommasi, 2011, Bioorganic & medicinal chemistry letters.

Role of the Klebsiella pneumoniae TolC porin in antibiotic efflux.

R. Tommasi, Alita A. Miller, Samir H. Moussa, 2019, Research in microbiology.

Titrating Levels of TolC in E. coli: A Sensitive Approach to Quantifying Efflux.

R. Tommasi, Alita A. Miller, Samir H. Moussa, 2018, ACS infectious diseases.

Rational design of a new antibiotic class for drug-resistant infections

S. McLeod, A. Ferguson, G. Drusano, 2021, Nature.

Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.

M. Glick, L. Hamann, Yipin Lu, 2017, Journal of medicinal chemistry.

Antibacterial Drug Discovery: Some Assembly Required.

R. Tommasi, Alita A. Miller, Ramkumar Iyer, 2018, ACS infectious diseases.

Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.

Dean G. Brown, R. Tommasi, Moriah M Gagnon, 2014, Journal of medicinal chemistry.

ESKAPEing the labyrinth of antibacterial discovery

Dean G. Brown, R. Tommasi, J. Manchester, 2015, Nature Reviews Drug Discovery.

ESKAPEing the labyrinth of antibacterial discovery

Dean G. Brown, R. Tommasi, J. Manchester, 2015, Nature Reviews Drug Discovery.

Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

M. Gowravaram, G. Basarab, V. Galullo, 2015, Scientific reports.

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

M. Gowravaram, G. Basarab, V. Galullo, 2015, Scientific Reports.

Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class.

K D Watenpaugh, K. Watenpaugh, R. Tommasi, 1998, Journal of medicinal chemistry.

Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.

W. Howe, K. Watenpaugh, R. Tommasi, 1996, Journal of medicinal chemistry.

Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones.

K. Watenpaugh, R. Tommasi, M. Janakiraman, 1998, Bioorganic & medicinal chemistry letters.

Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV)

John A. Tallarico, K. Kuhen, T. Bouwmeester, 2011, Proceedings of the National Academy of Sciences.

Structural Elucidation of a Putative Conidial Pigment Intermediate in Aspergillus parasiticus

J. J. Salvo, F. Hauser, R. Tommasi, 1993 .

Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282

Angela Tanudra, R. Tommasi, April Chen, 2020, ACS infectious diseases.

In vitro Characterization of ETX1317, a broad-spectrum β-lactamase inhibitor that restores and enhances β-lactam activity against multidrug resistant Enterobacteriales, including carbapenem-resistant strains.

S. McLeod, R. Tommasi, Alita A. Miller, 2020, ACS infectious diseases.

Covalent or trapped? PFG diffusion MAS NMR for combinatorial chemistry

R. Tommasi, M. Shapiro, J. Wareing, 1999 .

Atomic-scale characterization of conformational changes in the preQ₁ riboswitch aptamer upon ligand binding.

Andrea K Pomerantz, P. Petrone, L. Whitehead, 2011, Journal of molecular graphics & modelling.

Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

M. Gowravaram, G. Basarab, V. Galullo, 2015, Scientific Reports.

Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.

W. Cornell, R. Tommasi, S. Xue, 2009, Journal of medicinal chemistry.

Acinetobacter baumannii OmpA Is a Selective Antibiotic Permeant Porin.

R. Tommasi, Alita A. Miller, Samir H. Moussa, 2017, ACS infectious diseases.

4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.

J. Mckinney, L. Chiarelli, N. Dhar, 2014, Journal of medicinal chemistry.

N-arylaminonitriles as bioavailable peptidomimetic inhibitors of cathepsin B.

R. Tommasi, D. Farley, S. Cowen, 2003, Bioorganic & medicinal chemistry letters.

Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity.

Christopher B. Cooper, S. Butler, A. Narayan, 2019, ACS medicinal chemistry letters.

Global Surveillance of the Activity of Sulbactam Combined With the Novel β-lactamase Inhibitor ETX2514 Against Clinical Isolates of Acinetobacter baumannii From 2014

M. Hackel, R. Tommasi, B. Dejonge, 2016 .

Anti-Hepatitis C Virus Activity and Toxicity of Type III Phosphatidylinositol-4-Kinase Beta Inhibitors

P. Raman, R. Colvin, R. Tommasi, 2012, Antimicrobial Agents and Chemotherapy.

1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists.

E. Altmann, R. Wolf, K. Seuwen, 2010, Journal of medicinal chemistry.